Azora Therapeutics, Inc. (AZR)
NASDAQ: AZR · Real-Time Price · USD
3.870
+0.070 (1.84%)
At close: Nov 19, 2026, 4:00 PM EST
4.250
+0.380 (9.82%)
After-hours: Nov 19, 2026, 7:55 PM EST
Company Description
Azora Therapeutics, Inc. operates as a biopharmaceutical company that develops small molecule new chemical entities for the treatment of autoimmune and inflammatory diseases.
It offers treatment for dermatology and gastroenterology. The company's pipeline includes AT177, a colon‑targeted aryl hydrocarbon receptor (AhR) agonist to enable localized activation with limited systemic exposure in development for ulcerative colitis.
Azora Therapeutics, Inc. was formerly known as Meya Pharmaceuticals, Inc. and changed its name to Azora Therapeutics, Inc. in March 2019.
The company was incorporated in 2017 and is based in Encino, California.
Azora Therapeutics, Inc.
| Country | United States |
| Founded | 2017 |
| IPO Date | Jul 30, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
Contact Details
Address: 4267 Valley Meadow Road Encino, California 91436 United States | |
| Phone | (818) 276-6726 |
| Website | azoratherapeutics.com |
Stock Details
| Ticker Symbol | AZR |
| Exchange | NASDAQ |
| Reporting Currency | USD |
| CIK Code | 0001513525 |
| CUSIP Number | 054800107 |
| ISIN Number | US0548001074 |
| Employer ID | 80-0667150 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Julie Saiki Ph.D. | Co-Founder, Treasurer, Secretary and Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 17, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| Nov 13, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Nov 12, 2026 | 8-K | Current Report |
| Nov 12, 2026 | 10-Q | Quarterly Report |
| Nov 9, 2026 | 8-K | Current Report |
| Nov 3, 2026 | SCHEDULE 13G/A | Filing |
| Oct 28, 2026 | 8-K | Current Report |
| Oct 26, 2026 | EFFECT | Notice of Effectiveness |
| Oct 21, 2026 | 10-Q/A | [Amend] Quarterly report |
| Oct 21, 2026 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |